Pfizer to Acquire Excaliard in Major Pharma Deal
A team of Ropes & Gray attorneys is representing Pfizer in its agreement to acquire Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin scarring. The acquisition was announced on Nov. 22 and is expected to close before the end of the year. Excaliard’s lead product, EXC 001, is in Phase 2 development and is designed to interrupt the process of skin scarring by inhibiting expression of connective tissue growth factor. Pfizer plans to continue development of EXC 001 upon completion of the acquisition.
The Ropes & Gray team is led by securities & public companies partner Marko Zatylny and includes: securities & public companies partner Paul Kinsella; intellectual property transactions partner Mark Bellomy; tax partner David Saltzman; benefits partners Loretta Richard and Renata Ferrari; and associate Tara Fisher.